{
    "clinical_study": {
        "@rank": "100868", 
        "arm_group": [
            {
                "arm_group_label": "beta blocker and amiodarone", 
                "arm_group_type": "Experimental", 
                "description": "The inteventin will be that patients will receive beta blocker Bisoprolol in adjusted dose + Amiodarone per os starting 7 days before coronary by-pass surgery, 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge"
            }, 
            {
                "arm_group_label": "beta blocker and statin", 
                "arm_group_type": "Experimental", 
                "description": "The intervention will be that patients will receive beta blocker (Bisoprolol tab in adjusted dose)+ Rosuvastatin 20 mg. x 1 starting 7 days before coronary by-pass surgry untill discharge."
            }, 
            {
                "arm_group_label": "beta blocker", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will receive beta blocker (Bisoprolol tab in adjusted dose)."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to evaluate whether combined therapy with beta-blocker, amiodarone\n      and statine is better than beta-blocker alone for the prevention of atrial fibrillation\n      after coronary by-pass surgery."
        }, 
        "brief_title": "Atrial Fibrillation and By-pass Surgery", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients With Coronary Artery Disease Scheduled for by Pass Surgery", 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  significant coronary disease, sinus rhythm\n\n        Exclusion Criteria:\n\n          -  valvular disease, former by-pass surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "260", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01955759", 
            "org_study_id": "0115/09 - (2013)"
        }, 
        "intervention": [
            {
                "arm_group_label": "beta blocker and amiodarone", 
                "description": "starting 7 days before coronary by-pass surgery per os 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge", 
                "intervention_name": "Amiodarone  tab 200 mg x 3", 
                "intervention_type": "Drug", 
                "other_name": "cordarone"
            }, 
            {
                "arm_group_label": "beta blocker and statin", 
                "description": "starting 7 days before coronary by-pass surgery", 
                "intervention_name": "rosuvastatin 20 mg tab x1", 
                "intervention_type": "Drug", 
                "other_name": "crestor"
            }, 
            {
                "arm_group_label": [
                    "beta blocker and amiodarone", 
                    "beta blocker and statin", 
                    "beta blocker"
                ], 
                "description": "starting 7 days befoe coronary by-pass surgery", 
                "intervention_name": "beta blockers Bisoprolol in adjusted dose", 
                "intervention_type": "Drug", 
                "other_name": "zebeta"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Adrenergic beta-Antagonists", 
                "Bisoprolol", 
                "Amiodarone", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 15, 2013", 
        "location": {
            "contact": {
                "email": "osmanovic@bih.net.ba", 
                "last_name": "Enes Osmanovi\u0107", 
                "phone": "+387 66 725 744"
            }, 
            "facility": {
                "address": {
                    "city": "Tuzla", 
                    "country": "Bosnia and Herzegovina", 
                    "state": "TK", 
                    "zip": "75000"
                }, 
                "name": "Heart Center BH"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Bosnia and Herzegovina"
        }, 
        "number_of_arms": "3", 
        "official_title": "Pharmacologic Prophylaxis for Atrial Fibrillation Following Coronary By-Pass Surgery", 
        "overall_contact": {
            "email": "osmanovic@bhsrce.ba", 
            "last_name": "Enes Osmanovic, Master's degree", 
            "phone": "+387 66 725 744"
        }, 
        "overall_contact_backup": {
            "email": "goran.imamovic@fmc-ag.com", 
            "last_name": "Goran Imamovic"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Bosnia and Herzegovina: Federal Ministry of Health"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "outcome will be number of patients free from atrial fibrillation.", 
            "measure": "atrial fibrillation", 
            "safety_issue": "No", 
            "time_frame": "10 days on average during hospital stay after coronary by-pass surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01955759"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Heart Center BH Tuzla", 
            "investigator_full_name": "Enes Osmanovi\u0107", 
            "investigator_title": "Mr.med.sc.Dr Enes Osmanovic", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Heart Center BH Tuzla", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Heart Center BH Tuzla", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}